Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q4 EPS of ($0.09), $0.05 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.7 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.